What is the current valuation of the China Asthma COPD Drugs Market?

The market valuation was 2.12 USD Billion in 2024. Read More

What is the projected market size for the China Asthma COPD Drugs Market by 2035?

The market is projected to reach 3.0 USD Billion by 2035. Read More

What is the expected CAGR for the China Asthma COPD Drugs Market during the forecast period?

The expected CAGR for the market from 2025 to 2035 is 3.2%. Read More

Which drug types dominate the China Asthma COPD Drugs Market?

Bronchodilators and corticosteroids are among the leading drug types, with valuations of 1.2 and 0.9 USD Billion respectively. Read More

How does the market segment by route of administration appear?

Inhalation drugs lead the segment with a valuation of 1.2 USD Billion, followed by oral administration at 0.9 USD Billion. Read More

What demographic segments are targeted in the China Asthma COPD Drugs Market?

Adults represent the largest demographic segment, with a valuation of 1.5 USD Billion. Read More

Which therapeutic areas are prioritized in the market?

Asthma and Chronic Obstructive Pulmonary Disease are prioritized, with valuations of 1.2 and 1.0 USD Billion respectively. Read More

Who are the key players in the China Asthma COPD Drugs Market?

Key players include AstraZeneca, Novartis, GSK, and Boehringer Ingelheim. Read More

What is the market outlook for patients with comorbidities?

The market for patients with comorbidities is projected to be valued at 0.25 USD Billion. Read More

How does the market for injectable drugs compare to other routes of administration?

Injectable drugs are valued at 0.4 USD Billion, indicating a smaller share compared to inhalation and oral routes. Read More

China Asthma COPD Drugs Market

ID: MRFR/HC/47725-HCR 200 Pages Vikita Thakur Last Updated: September 17, 2026

China Asthma COPD Drugs Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)3.2%

2024 Market Size$ 2.12 Billion

2025 Market Size$ 2.19 Billion

2035 Market Size$ 3 Billion

Key Players

AstraZeneca

Novartis

GSK

Boehringer Ingelheim

Teva Pharmaceutical Industries

Merck & Co.

Trends

Rising Prevalence of Respiratory Diseases
Government Healthcare Initiatives
Shift Towards Personalized Medicine

Opportunities

Aging Population
Rising Air Pollution Levels
Growing Awareness and Education

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 China Asthma COPD Drugs Market, BY Drug Type (USD Billion)
  1. 4.1.1 Bronchodilators
  2. 4.1.2 Corticosteroids
  3. 4.1.3 Combination Therapy
  4. 4.1.4 Leukotriene Modifiers
  5. 4.1.5 Monoclonal Antibodies
2. 4.2 China Asthma COPD Drugs Market, BY Route of Administration (USD Billion)
  1. 4.2.1 Inhalation
  2. 4.2.2 Oral
  3. 4.2.3 Injectable
  4. 4.2.4 Nasal
  5. 4.2.5 Transdermal
3. 4.3 China Asthma COPD Drugs Market, BY Patient Demographics (USD Billion)
  1. 4.3.1 Children
  2. 4.3.2 Adults
  3. 4.3.3 Elderly
  4. 4.3.4 Pregnant Women
  5. 4.3.5 Patients with Comorbidities
4. 4.4 China Asthma COPD Drugs Market, BY Therapeutic Area (USD Billion)
  1. 4.4.1 Asthma
  2. 4.4.2 Chronic Obstructive Pulmonary Disease
  3. 4.4.3 Allergic Rhinitis
  4. 4.4.4 Respiratory Infections
  5. 4.4.5 Pulmonary Hypertension
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the China Asthma COPD Drugs Market
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the China Asthma COPD Drugs Market
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 AstraZeneca (GB)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Novartis (CH)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 GSK (GB)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Boehringer Ingelheim (DE)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Teva Pharmaceutical Industries (IL)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Merck & Co. (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Roche (CH)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Sanofi (FR)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Pfizer (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 CHINA MARKET ANALYSIS BY DRUG TYPE
3. 6.3 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
4. 6.4 CHINA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
5. 6.5 CHINA MARKET ANALYSIS BY THERAPEUTIC AREA
6. 6.6 KEY BUYING CRITERIA OF CHINA ASTHMA COPD DRUGS MARKET
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF CHINA ASTHMA COPD DRUGS MARKET
9. 6.9 DRIVERS IMPACT ANALYSIS: CHINA ASTHMA COPD DRUGS MARKET
10. 6.10 RESTRAINTS IMPACT ANALYSIS: CHINA ASTHMA COPD DRUGS MARKET
11. 6.11 SUPPLY / VALUE CHAIN: CHINA ASTHMA COPD DRUGS MARKET
12. 6.12 CHINA ASTHMA COPD DRUGS MARKET, BY DRUG TYPE, 2024 (% SHARE)
13. 6.13 CHINA ASTHMA COPD DRUGS MARKET, BY DRUG TYPE, 2024 TO 2035 (USD Billion)
14. 6.14 CHINA ASTHMA COPD DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
15. 6.15 CHINA ASTHMA COPD DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
16. 6.16 CHINA ASTHMA COPD DRUGS MARKET, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE)
17. 6.17 CHINA ASTHMA COPD DRUGS MARKET, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Billion)
18. 6.18 CHINA ASTHMA COPD DRUGS MARKET, BY THERAPEUTIC AREA, 2024 (% SHARE)
19. 6.19 CHINA ASTHMA COPD DRUGS MARKET, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Billion)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DRUG TYPE, 2026-2035 (USD Billion)
  2. 7.2.2 BY ROUTE OF ADMINISTRATION, 2026-2035 (USD Billion)
  3. 7.2.3 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Billion)
  4. 7.2.4 BY THERAPEUTIC AREA, 2026-2035 (USD Billion)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Enquiry

Customize Report

China Asthma COPD Drugs Market Segmentation

China Asthma COPD Drugs Market By Drug Type (USD Billion, 2022-2035)

Bronchodilators
Corticosteroids
Combination Therapy
Leukotriene Modifiers
Monoclonal Antibodies

China Asthma COPD Drugs Market By Route of Administration (USD Billion, 2022-2035)

Inhalation
Oral
Injectable
Nasal
Transdermal

China Asthma COPD Drugs Market By Patient Demographics (USD Billion, 2022-2035)

Children
Adults
Elderly
Pregnant Women
Patients with Comorbidities

China Asthma COPD Drugs Market By Therapeutic Area (USD Billion, 2022-2035)

Asthma
Chronic Obstructive Pulmonary Disease
Allergic Rhinitis
Respiratory Infections
Pulmonary Hypertension

Certified Researchers

Enquiry

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”

Guilherme Gomes Martins Product Management Director

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”